![]()
Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Stock analysts at Jefferies Financial Group upped their FY2019 earnings per share estimates for shares of Spring Bank Pharmaceuticals in a research note issued on Wednesday, January 29th. Jefferies Financial Group analyst M. Raycroft now forecasts that the company will post earnings of ($1.67) per share for the year, up from their previous estimate of ($1.69). Jefferies Financial Group has a “Hold” rating and a $1.50 price objective on the stock. Jefferies Financial Group also issued estimates for Spring Bank Pharmaceuticals’ Q4 2019 earnings at ($0.47) EPS, FY2020 earnings at ($0.82) EPS, FY2021 earnings at ($0.52) EPS, FY2022 earnings at ($0.83) EPS and FY2023 earnings at ($0.38) EPS.
Other equities research analysts have also issued reports about the stock. B. Riley reissued a “neutral” rating and set a $2.00 target price (down from $16.00) on shares of Spring Bank Pharmaceuticals in a research note on Monday, December 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Spring Bank Pharmaceuticals in a research report on Friday, December 20th. Piper Jaffray Companies cut their price target on Spring Bank Pharmaceuticals from $10.00 to $1.70 in a research note on Monday, December 30th. ValuEngine raised Spring Bank Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Finally, Zacks Investment Research upgraded Spring Bank Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Thursday, January 16th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $10.12.
SBPH opened at $1.13 on Monday. Spring Bank Pharmaceuticals has a fifty-two week low of $1.11 and a fifty-two week high of $11.00. The company has a debt-to-equity ratio of 0.52, a quick ratio of 12.18 and a current ratio of 12.18. The company has a fifty day moving average of $1.91 and a two-hundred day moving average of $3.22. The stock has a market capitalization of $18.78 million, a price-to-earnings ratio of -0.84 and a beta of 0.53.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its earnings results on Thursday, November 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.19.
A number of large investors have recently bought and sold shares of SBPH. Jane Street Group LLC purchased a new position in Spring Bank Pharmaceuticals during the second quarter valued at $59,000. Susquehanna International Group LLP purchased a new stake in shares of Spring Bank Pharmaceuticals during the second quarter worth about $91,000. Morse Asset Management Inc raised its position in shares of Spring Bank Pharmaceuticals by 256.8% during the 3rd quarter. Morse Asset Management Inc now owns 42,935 shares of the company’s stock worth $148,000 after purchasing an additional 30,900 shares during the last quarter. Morgan Stanley raised its position in shares of Spring Bank Pharmaceuticals by 102.7% during the 2nd quarter. Morgan Stanley now owns 44,963 shares of the company’s stock worth $166,000 after purchasing an additional 22,776 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Spring Bank Pharmaceuticals by 21.1% in the 3rd quarter. Millennium Management LLC now owns 100,077 shares of the company’s stock valued at $350,000 after buying an additional 17,465 shares in the last quarter. Institutional investors own 39.15% of the company’s stock.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).
Read More: Treasury Bonds
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
